PLSE
Pulse Biosciences Inc

1,932
Mkt Cap
$958.23M
Volume
214,315.00
52W High
$25.00
52W Low
$13.77
PE Ratio
-12.46
PLSE Fundamentals
Price
$14.40
Prev Close
$14.14
Open
$14.00
50D MA
$17.04
Beta
1.21
Avg. Volume
160,837.96
EPS (Annual)
-$0.9176
P/B
10.33
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Pulse Biosciences is Now Oversold (PLSE)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...
Nasdaq News: Markets·2d ago
News Placeholder
More News
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts...
MarketBeat·8d ago
News Placeholder
Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced plans...
Business Wire·8d ago
News Placeholder
Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Lags Revenue Estimates
Pulse Biosciences (PLSE) delivered earnings and revenue surprises of +6.45% and -82.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9d ago
News Placeholder
Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced the...
Business Wire·22d ago
News Placeholder
Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced it...
Business Wire·23d ago
News Placeholder
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced that...
Business Wire·30d ago
News Placeholder
Pulse Biosciences Unveils Promising First-in-Human Data for nPulse
PLSE unveils strong first-in-human data for its nPulse Cardiac Surgical System, showcasing safety, speed, and durable AF treatment potential.
Zacks·1mo ago
News Placeholder
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced...
Business Wire·1mo ago
News Placeholder
Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study
PLSE wins FDA IDE approval for its NANOCLAMP AF study, advancing nsPFA tech as a novel option in atrial fibrillation surgery.
Zacks·2mo ago

Latest PLSE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.